Literature DB >> 21162604

Overview of venous thromboembolism.

José Ignacio Abad Rico1, Juan Vicente Llau Pitarch, Eduardo Rocha.   

Abstract

Thrombosis occurs at sites of injury to the vessel wall, by inflammatory processes leading to activation of platelets, platelet adherence to the vessel wall and the formation of a fibrin network. A thrombus that goes on to occlude a blood vessel is known as a thromboembolism. Venous thromboembolism begins with deep vein thrombosis (DVT), which forms in the deep veins of the leg (calf) or pelvis. In some cases, the DVT becomes detached from the vein and is transported to the right-hand side of the heart, and from there to the pulmonary arteries, giving rise to a pulmonary embolism (PE). Certain factors predispose patients toward the development of venous thromboembolism (VTE), including surgery, trauma, hospitalization, immobilization, cancer, long-haul travel, increased age, obesity, major medical illness and previous VTE; in addition, there may also be a genetic component to VTE. VTE is responsible for a substantial number of deaths per annum in Europe. Anticoagulants are the mainstay of both VTE treatment and VTE prevention, and many professional organizations have published guidelines on the appropriate use of anticoagulant therapies for VTE. Treatment of VTE aims to prevent morbidity and mortality associated with the disease, and any long-term complications such as VTE recurrence or post-thrombotic syndrome. Generally, guidelines recommend the use of low molecular weight heparins (LMWH), unfractionated heparin (UFH) or fondaparinux for the pharmacological prevention and treatment of VTE, with the duration of therapy varying according to the baseline characteristics and risk profile of the individual. Despite evidence showing that the use of anticoagulation prevents VTE, the availability of several convenient, effective anticoagulant therapies and the existence of clear guideline recommendations, thromboprophylaxis is underused, particularly in patients not undergoing surgery. Greater adherence to guideline-recommended therapies, such as LMWH, which can be administered on an outpatient basis, should reduce the mortality associated with this preventable disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21162604     DOI: 10.2165/1158583-S0-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  37 in total

Review 1.  Venous thromboembolism: diagnosis and management of deep venous thrombosis.

Authors:  Wai Khoon Ho; Graeme J Hankey; Cindy H Lee; John W Eikelboom
Journal:  Med J Aust       Date:  2005-05-02       Impact factor: 7.738

2.  An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.

Authors:  M M Samama
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

3.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

4.  Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Authors:  Vincenza Snow; Amir Qaseem; Patricia Barry; E Rodney Hornbake; Jonathan E Rodnick; Timothy Tobolic; Belinda Ireland; Jodi B Segal; Eric B Bass; Kevin B Weiss; Lee Green; Douglas K Owens
Journal:  Ann Intern Med       Date:  2007-01-29       Impact factor: 25.391

Review 5.  Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.

Authors:  Marcelo P V Gomes; Steven R Deitcher
Journal:  Arch Intern Med       Date:  2004-10-11

6.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

7.  Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound.

Authors:  A Cogo; A W Lensing; P Prandoni; J Hirsh
Journal:  Arch Intern Med       Date:  1993-12-27

8.  Familial segregation of venous thromboembolism.

Authors:  J A Heit; M A Phelps; S A Ward; J P Slusser; T M Petterson; M De Andrade
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

9.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Authors:  Adam Torbicki; Arnaud Perrier; Stavros Konstantinides; Giancarlo Agnelli; Nazzareno Galiè; Piotr Pruszczyk; Frank Bengel; Adrian J B Brady; Daniel Ferreira; Uwe Janssens; Walter Klepetko; Eckhard Mayer; Martine Remy-Jardin; Jean-Pierre Bassand
Journal:  Eur Heart J       Date:  2008-08-30       Impact factor: 29.983

View more
  4 in total

Review 1.  Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.

Authors:  Matt Shirley; Sohita Dhillon
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

2.  Filter tilting and retrievability of the Celect and Denali inferior vena cava filters using propensity score-matching analysis.

Authors:  Jae Heung Bae; Sang Yub Lee
Journal:  Eur J Radiol Open       Date:  2018-09-10

Review 3.  ERO1-PDI Redox Signaling in Health and Disease.

Authors:  Vishwanath Jha; Tripti Kumari; Vijayprakash Manickam; Zahra Assar; Kirk L Olson; Jeong-Ki Min; Jaehyung Cho
Journal:  Antioxid Redox Signal       Date:  2021-07-13       Impact factor: 8.401

4.  Real-Time Label-Free Embolus Detection Using In Vivo Photoacoustic Flow Cytometry.

Authors:  Mazen A Juratli; Yulian A Menyaev; Mustafa Sarimollaoglu; Eric R Siegel; Dmitry A Nedosekin; James Y Suen; Alexander V Melerzanov; Tareq A Juratli; Ekaterina I Galanzha; Vladimir P Zharov
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.